A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines

NCT06946160 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
146
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Espad Pharmed